Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020 Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results expected to be presented in Q3 2019. Appointed Adam Gridley as Chief Executive Officer Conference call and live webcast

Conference Call Scheduled for 8:30am ET / 1:30pm BST JERUSALEM , Aug. 15, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the second quarter and six months ended June 30, 2019 before the U.S.

JERUSALEM, Israel , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip Schwartz , Ph.D., former CEO of Entera since the Company’s inception in 2010, will continue with the

JERUSALEM , July 02, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH (1-34) tablet. This double blinded, placebo controlled, dose-ranging study will evaluate three different

Phase 2b Study for oral PTH in osteoporosis to begin by mid-year 2019 Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Data processing and statistical analysis are ongoing, with results expected to be presented in 2H 2019. Appointed Dana Yaacov-Garbeli, CPA, as interim

Positive feedback and guidance from the US FDA regarding development plans for Oral PTH in osteoporosis Entered into research collaboration and license agreement with Amgen , potential for up to $270 million in milestone payments, Amgen’s exercise of options to select additional programs and

JERUSALEM , March 28, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018 , with the U.S. Securities and Exchange Commission . A copy of the Annual Report available in the Investor Relations

Conference Call Scheduled for 10am Eastern Time / 2pm Greenwich Mean Time JERUSALEM , March 27, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the fourth quarter and year ended December 31, 2018 before the market open on Thursday,

JERUSALEM , March 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that Mira Rosenzweig , Chief Financial Officer, will be leaving the Company in mid-April 2019 on amicable terms to pursue other professional opportunities closer to her home. Ms.

JERUSALEM , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration ( FDA ) to discuss the Company’s development plan for Oral PTH for the treatment of osteoporosis.